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Objectives: 
 
We sought to compare three modalities of measurements of
the aortic annulus, transthoracic (TTE), transesophageal echocardiography
(TEE), and multislice computed tomography (MSCT), and to evaluate their
potential clinical impact on transcatheter aortic valve implantation (TAVI)
strategy.
 
Background:
 
 TAVI is an alternative to surgery for high-risk patients with
severe aortic stenosis (AS). Exact measurement of the aortic annulus is critical
for appropriate patient’s selection and successful implantation.
 
Methods:
 
 Annulus diameter was measured using TTE, TEE and MSCT in
45 consecutive patients with severe AS, referred for TAVI. TAVI was per-
formed using a balloon expendable valve (Edwards-Sapien). The TAVI
strategy (decision to implant and choice of the prosthesis’ size) was based on
manufacturer’s recommendations.
 
Results:
 
 Correlations between methods were good but absolute difference
between MSCT and TTE (1.22±1.3 mm) or TEE (1.52±1.1 mm) was signifi-
cantly larger than the absolute difference between TTE and TEE (0.6±0.8 mm,
p=0.03 and p<0.0001 respectively). As regard to TAVI strategy, agreement
between TTE and TEE was good overall (Kappa 0.68) but the TAVI strategy
would have been different in 8 patients (17%). Agreement between MSCT and
TTE or TEE was only modest (Kappa 0.28 and 0.27) and a decision based on
MSCT measurements would have modified the TAVI strategy in a large
number of patients (40% and 42%). Implantation was performed in 34 patients
(76%) based on TEE measurements and was successful in all but one patient
who had a grade 3 aortic regurgitation.
 
Conclusions: 
 
In this group of patients with AS referred for TAVI, mea-
surements of the aortic annulus using TTE, TEE and MSCT were close but not
identical and the method used has important potential clinical implications on
TAVI strategy. In the absence of gold standard, a strategy based on TEE mea-
surements provided good clinical results.
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Purpose:
 
 We evaluate clinical characteristics, management and prognosis
of patients (Pts) with severe aortic stenosis (AS) hospitalized in a university
hospital offering all therapeutic options: AVR, balloon aortic valvuloplasty
(BAV) and transcutaneous heart valve implantation (TAVI) using the Edwards
Sapien bioprosthesis.
 
Methods:
 
 We included 211 Pts with severe AS (EOA < 1 cm
 
2
 
 and/or 0.6
cm
 
2
 
/m
 
2
 
), hospitalised between July, 2006 and July, 2007 in our center. Clin-
ical, echocardiographic and angiographic characteristics, logistic EuroSCORE
and STS score were evaluated. A prospective clinical and echocardiographic
follow-up was performed at 1-year.
 
Results:
 
 211 Pts (79 ± 9 years; 53% female) were included in the study.
58% of Pts were > 80 years old. 65% of Pts were highly symptomatic (NYHA
3-4). After multidisciplinary evaluation, 92 (43.6%) patients were referred to
surgical AVR, 20 (9.5%) to TAVI, 62 (29.4%) to BAV and 37 (17.5%) were
maintained on medical treatment alone. Pts treated by AVR were younger
(74+/-9 vs 84+/-5, p< .0001) and had less frequent history of myocardial inf-
arction (p=0.003) or coronary artery bypass grafts (p=0.0002), less renal
failure (p<0.001), less severe lung disease (p=0.009), and less demetia
(p=0.0002) than the 3 other groups. Operative risk was lower in the AVR
group as assessed by Euroscore (8% vs 25%, p< .0001) and STS score (4.4 vs
13.0%, p< .0001). At one year, survival was excellent in the AVR group
(99%) with no procedural death. At the opposite, 51% of Pts treated medically
died. BAV improved symptoms (24% in NYHA IV vs 58% at baseline) and
survival was 66% at 1-year. Survival rate in the TAVI group was 79% with
marked symptoms improvement (70% of Pts in NYHA 1-2 vs 1% at baseline).
 
Conclusions:
 
 Patients with severe AS represent a very heterogeneous pop-
ulation. Surgical AVR remains the reference treatment with excellent results.
However, TAVI is a promising alternative treatment in many Pts with heavy
and multiple comorbidities.
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Background:
 
 We recently reported an atypical possible prosthetic valve
infective endocarditis (PVIE) occurring on a stentless Cryolife O’Brien®
aortic bioprosthesis without inflammatory markers, negative blood cultures but
anatomic damage suggestive of IE and aimed to look for other cases.
 
Methods:
 
 We reviewed all cases of possible or definite aortic PVIE
according to the modified Duke criteria hospitalized in our institution between
January 2002 and March 2008.
 
Results:
 
 60 patients with possible or definite aortic PVIE were admitted
during this period (26 mechanical prosthesis, 11 stented bioprosthesis and 23
stentless Cryo-Life O’Brien® bioprosthesis). Compared to mechanical or
stented prosthesis, patients with stentless valve presented less frequently with
fever (39% vs. 77% and 91%, p=0.003), tended to present more frequently in
congestive heart failure (54% vs. 23% and 36%, p=0.10), less frequently with
positive blood cultures (44% vs. 65% and 82%, p=0.08) and with lower CRP
levels (69±70 mg/L vs. 144±106 mg/L and 145±123 mg/L, p=0.02). Patients
with stentless valve also presented less frequently with vegetations (22% vs.
58% and 63%, p=0.01) but more frequently with valve dehiscence (68% vs.
23% and 22%, p=0.006) and severe aortic regurgitation (65% vs. 23% and
36%, p=0.01). 40 patients were operated on within 30 days, more frequently
in the stentless group (83% vs. 61% and 45% respectively, p=0.07). Compared
to the previously reported incidence of stentless PVIE at our institution
(1.5%), we observed a striking increase incidence after 2004 (>7%).
 
Conclusion:
 
 We report a frequent and atypical clinical and microbiological
presentation of possible PVIE occurring on stentless bioprosthesis and a
striking increased incidence after 2004 which corresponds to changes in the
manufacturing process. Clinicians should be aware of this atypical clinical pre-
sentation. The stentless Cryo-Life O’Brien ® bioprosthesis is not anymore
implanted at our institution.
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